Evidence map›Paper›PMID 40072751›Full record

ArticleMedical oncology (Northwood, London, England)2025

Integrative approach to decipher pharmacological mechanism of Cinnamomum zeylanicum essential oil in prostate cancer.

Debajani Mohanty, Sucheesmita Padhee, Arpita Priyadarshini, Rout George Kerry, Biswabhusan Dash, Ambika Sahoo, Sudipta Jena, Pratap Chandra Panda, Haseeb Ahmad Khan, Sanghamitra Nayak and 1 more

Abstract read
PubMed Publisher
In one paragraph

Article in Medical oncology (Northwood, London, England), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Debajani MohantyCentre for Biotechnology, Siksha O Anusandhan (Deemed to Be University), Bhubaneswar, Odisha, 751003, India.
Sucheesmita PadheeCentre for Biotechnology, Siksha O Anusandhan (Deemed to Be University), Bhubaneswar, Odisha, 751003, India.
Arpita PriyadarshiniCentre for Biotechnology, Siksha O Anusandhan (Deemed to Be University), Bhubaneswar, Odisha, 751003, India.
Rout George KerryCentre for Biotechnology, Siksha O Anusandhan (Deemed to Be University), Bhubaneswar, Odisha, 751003, India.
Biswabhusan DashCentre for Biotechnology, Siksha O Anusandhan (Deemed to Be University), Bhubaneswar, Odisha, 751003, India.
Ambika SahooCentre for Biotechnology, Siksha O Anusandhan (Deemed to Be University), Bhubaneswar, Odisha, 751003, India.
Sudipta JenaCentre for Biotechnology, Siksha O Anusandhan (Deemed to Be University), Bhubaneswar, Odisha, 751003, India.
Pratap Chandra PandaCentre for Biotechnology, Siksha O Anusandhan (Deemed to Be University), Bhubaneswar, Odisha, 751003, India.
Haseeb Ahmad KhanDepartment of Biochemistry, College of Science, King Saud University, 11451, Riyadh, Saudi Arabia.
Sanghamitra NayakCentre for Biotechnology, Siksha O Anusandhan (Deemed to Be University), Bhubaneswar, Odisha, 751003, India.
Asit RayCentre for Biotechnology, Siksha O Anusandhan (Deemed to Be University), Bhubaneswar, Odisha, 751003, India. asitray@soa.ac.in.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Prostate cancer has garnered much importance in recent years due to its rising incidence and mortality among men worldwide. The ineffectiveness of existing therapies and adverse events associated with conventional treatment have led patients to turn towards traditional medicine for the management of prostate cancer. Cinnamomum zeylanicum bark essential oil (CZEO) possesses promising anticancer properties, yet the exact mechanism of action of CZEO for the management of prostate cancer remains unclear. Therefore, the current study tried to elucidate the bioactive components and key potential targets through which CZEO may exert its anticancer effect for treating prostate cancer. Fifty-nine constituents were identified by GC-MS, of which 52 were drug-like constituents. A total of 2847 targets related to CZEO and 2283 targets related to prostate cancer were obtained from public databases and the GEO dataset. Twenty-three overlapping targets exist between CZEO and disease targets. Compound-disease-target network analysis revealed camphor, eugenol, methyl eugenol, trans farnesyl acetate and nerol as the core bioactive ingredients of CZEO. The topological screening of the PPI network revealed BCL2, TNF, NFKBIA, CREBBP and IL7R as potential hub targets. These hub targets were validated based on mRNA expression level, pathological stages, overall survival, immune infiltrate and genetic alteration analysis in prostate adenocarcinoma and normal patients. KEGG enrichment analysis proposed that CZEO exhibits its anticancer effect mainly by modulating the PI3-AKT and MAPK signalling pathway. Moreover, molecular docking and dynamics simulation studies revealed a good binding affinity of these core compounds with TNF, NFKBIA and BCL2. CZEO exhibited a remarkable anti-proliferative effect against PC-3 cells with an IC

Indexed as

Cinnamomum zeylanicumOils, VolatileProstatic NeoplasmsApoptosisCell Line, TumorCell ProliferationHumansMaleOils, VolatileEssential oilMultitarget effectsNatural compoundsNetwork pharmacologyProstate cancer

Identifiers

PMID40072751

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.